S&P 500   3,294.79 (+0.42%)
DOW   27,147.51 (+0.00%)
QQQ   269.32 (+0.68%)
AAPL   110.09 (+0.01%)
MSFT   204.82 (+1.13%)
FB   252.22 (+1.64%)
GOOGL   1,444.30 (+0.99%)
AMZN   3,081.99 (+4.10%)
NVDA   496.22 (-0.89%)
TSLA   427.88 (-4.79%)
BABA   272.95 (-0.32%)
CGC   15.94 (+1.27%)
GE   6.24 (-1.73%)
MU   49.16 (+0.02%)
AMD   76.36 (-2.03%)
T   28.52 (-0.38%)
F   6.79 (-1.16%)
ACB   7.29 (+15.35%)
GILD   63.44 (-1.20%)
NFLX   484.97 (-0.49%)
DIS   126.16 (+0.60%)
BAC   23.83 (-2.62%)
BA   155.40 (-0.61%)
S&P 500   3,294.79 (+0.42%)
DOW   27,147.51 (+0.00%)
QQQ   269.32 (+0.68%)
AAPL   110.09 (+0.01%)
MSFT   204.82 (+1.13%)
FB   252.22 (+1.64%)
GOOGL   1,444.30 (+0.99%)
AMZN   3,081.99 (+4.10%)
NVDA   496.22 (-0.89%)
TSLA   427.88 (-4.79%)
BABA   272.95 (-0.32%)
CGC   15.94 (+1.27%)
GE   6.24 (-1.73%)
MU   49.16 (+0.02%)
AMD   76.36 (-2.03%)
T   28.52 (-0.38%)
F   6.79 (-1.16%)
ACB   7.29 (+15.35%)
GILD   63.44 (-1.20%)
NFLX   484.97 (-0.49%)
DIS   126.16 (+0.60%)
BAC   23.83 (-2.62%)
BA   155.40 (-0.61%)
S&P 500   3,294.79 (+0.42%)
DOW   27,147.51 (+0.00%)
QQQ   269.32 (+0.68%)
AAPL   110.09 (+0.01%)
MSFT   204.82 (+1.13%)
FB   252.22 (+1.64%)
GOOGL   1,444.30 (+0.99%)
AMZN   3,081.99 (+4.10%)
NVDA   496.22 (-0.89%)
TSLA   427.88 (-4.79%)
BABA   272.95 (-0.32%)
CGC   15.94 (+1.27%)
GE   6.24 (-1.73%)
MU   49.16 (+0.02%)
AMD   76.36 (-2.03%)
T   28.52 (-0.38%)
F   6.79 (-1.16%)
ACB   7.29 (+15.35%)
GILD   63.44 (-1.20%)
NFLX   484.97 (-0.49%)
DIS   126.16 (+0.60%)
BAC   23.83 (-2.62%)
BA   155.40 (-0.61%)
S&P 500   3,294.79 (+0.42%)
DOW   27,147.51 (+0.00%)
QQQ   269.32 (+0.68%)
AAPL   110.09 (+0.01%)
MSFT   204.82 (+1.13%)
FB   252.22 (+1.64%)
GOOGL   1,444.30 (+0.99%)
AMZN   3,081.99 (+4.10%)
NVDA   496.22 (-0.89%)
TSLA   427.88 (-4.79%)
BABA   272.95 (-0.32%)
CGC   15.94 (+1.27%)
GE   6.24 (-1.73%)
MU   49.16 (+0.02%)
AMD   76.36 (-2.03%)
T   28.52 (-0.38%)
F   6.79 (-1.16%)
ACB   7.29 (+15.35%)
GILD   63.44 (-1.20%)
NFLX   484.97 (-0.49%)
DIS   126.16 (+0.60%)
BAC   23.83 (-2.62%)
BA   155.40 (-0.61%)
Log in
NASDAQ:EVGN

Evogene Stock Forecast, Price & News

$3.50
+0.13 (+3.86 %)
(As of 09/22/2020 01:11 PM ET)
Add
Compare
Today's Range
$3.05
Now: $3.50
$3.73
50-Day Range
$1.04
MA: $1.86
$3.09
52-Week Range
$0.75
Now: $3.50
$3.50
Volume38,884 shs
Average Volume192,473 shs
Market Capitalization$90.13 million
P/E RatioN/A
Dividend YieldN/A
Beta1.41
Evogene Ltd., a biotechnology company, engages in developing various products for various life science markets through the use of computational predictive biology platform in the United States, Germany, and internationally. It discovers and develops products in various areas, including ag-chemicals, ag-biologicals, seed traits, integrated castor oil ag-solutions, and human microbiome-based therapeutics. The company operates through three segments: Evogene, Evofuel, and Biomica. The Evogene segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. This segment develops seed traits enhancing plant yield and tolerance to abiotic stresses, such as enhanced tolerance to drought, heat, and salinity, as well as seed traits for enhancing plant resistance to biotic stresses, including resistance to diseases, pests, and insects; novel herbicides; and bio-stimulants and bio-pesticides. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Evofuel segment develops enhanced castor bean seeds to serve as a feedstock source for biofuel and other industrial uses. The Biomica segment discovers and develops human microbiome-based therapeutics for the treatment of immune-mediated and infectious diseases. The company also provides medical cannabis products. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF, Corteva, ICL, Monsanto, Bayer, and others. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
Read More
Evogene logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.46 out of 5 stars


Industry, Sector and Symbol

Industry Agricultural chemicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EVGN
CUSIPN/A
Phone972-8931-1900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$750,000.00
Book Value$2.34 per share

Profitability

Net Income$-18,110,000.00
Net Margins-3,545.22%

Miscellaneous

EmployeesN/A
Market Cap$90.13 million
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
$3.50
+0.13 (+3.86 %)
(As of 09/22/2020 01:11 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EVGN News and Ratings via Email

Sign-up to receive the latest news and ratings for EVGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Evogene (NASDAQ:EVGN) Frequently Asked Questions

How has Evogene's stock been impacted by Coronavirus (COVID-19)?

Evogene's stock was trading at $0.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EVGN shares have increased by 253.5% and is now trading at $3.50.
View which stocks have been most impacted by COVID-19
.

When is Evogene's next earnings date?

Evogene is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Evogene
.

How were Evogene's earnings last quarter?

Evogene Ltd (NASDAQ:EVGN) issued its quarterly earnings data on Wednesday, August, 5th. The biotechnology company reported ($0.16) earnings per share for the quarter. The biotechnology company had revenue of $0.30 million for the quarter. Evogene had a negative return on equity of 35.78% and a negative net margin of 3,545.22%.
View Evogene's earnings history
.

Are investors shorting Evogene?

Evogene saw a increase in short interest in August. As of August 31st, there was short interest totaling 100,800 shares, an increase of 90.9% from the August 15th total of 52,800 shares. Based on an average daily trading volume, of 340,500 shares, the short-interest ratio is presently 0.3 days. Currently, 0.5% of the shares of the stock are short sold.
View Evogene's Short Interest
.

Who are some of Evogene's key competitors?

What other stocks do shareholders of Evogene own?

Who are Evogene's key executives?

Evogene's management team includes the following people:
  • Mr. Ofer Haviv, CEO & Pres (Age 53)
  • Ms. Dorit Kreiner, Interim Chief Financial Officer
  • Mr. Mark Kapel, Exec. VP of Technology (Age 42)
  • Dr. Eyal Emmanuel, Chief Scientific Officer (Age 46)
  • Ms. Sigal Fattal, Exec. Officer (Age 48)

What is Evogene's stock symbol?

Evogene trades on the NASDAQ under the ticker symbol "EVGN."

Who are Evogene's major shareholders?

Evogene's stock is owned by a number of retail and institutional investors. Top institutional investors include UBS Group AG (1.23%) and Eidelman Virant Capital (0.25%).

Which major investors are selling Evogene stock?

EVGN stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG.

Which major investors are buying Evogene stock?

EVGN stock was bought by a variety of institutional investors in the last quarter, including Eidelman Virant Capital.

How do I buy shares of Evogene?

Shares of EVGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Evogene's stock price today?

One share of EVGN stock can currently be purchased for approximately $3.50.

How big of a company is Evogene?

Evogene has a market capitalization of $90.13 million and generates $750,000.00 in revenue each year.

What is Evogene's official website?

The official website for Evogene is www.evogene.com.

How can I contact Evogene?

Evogene's mailing address is 13 GAD FEINSTEIN STREET PARK REHOVOT P.O.B 2100, REHOVOT L3, 76121. The biotechnology company can be reached via phone at 972-8931-1900 or via email at [email protected]

This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.